Cancer cells can treat tumors

Cancer cells can treat tumors.
New analyse suggests that many cancer cells are equipped with a kindly of suicide pill: a protein on their surfaces that gives them the ability to send an "eat me" consequential to immune cells. The challenge now, the researchers say, is to count on out how to coax cancer cells into emitting the signal rather than a dangerous "don't eat me" signal aunty ki gand mari thuk laga kar. A on published online Dec 22 2010 in Science Translational Medicine reports that the cells stir out the enticing "eat me" signal by displaying the protein calreticulin.

But another molecule, called CD47, allows most cancer cells to elude destruction by sending the facing signal: "Don't eat me". In earlier research, Stanford University School of Medicine scientists found that an antibody that blocks CD47 - turning off the indicate - could helper fight cancer, but mysteries remained how much is innoxa blue eye drop sold in lagos. "Many normal cells in the body have CD47, and yet those cells are not feigned by the anti-CD47 antibody," Mark Chao, a Stanford graduate student and the study's lead author, said in a university newscast release.

And "At that time, we knew that anti-CD47 antibody care selectively killed only cancer cells without being toxic to most normal cells, although we didn't know why". Now, the green research has shown that calreticulin exists in a variety of cancers, including some types of leukemia, non-Hodgkin's lymphoma and bladder, intelligence and ovarian cancers.

So "This research demonstrates that the aim that blocking the CD47 'don't eat me' signal works to kill cancer is that leukemias, lymphomas and many unshakable tumors also display a calreticulin 'eat me' signal," Dr Irving Weissman, conductor of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and a co-principal investigator of the study, said in the release. "The inquire into also shows that most normal cell populations don't publicize calreticulin and are, therefore, not depleted when we expose them to a blocking anti-CD47 antibody".

The next walk is to understand how calreticulin works. "We want to know how it contributes to the disease process and what is episode in the cell that causes the protein to move to the cell surface," Dr Ravindra Majeti, an helper professor of hematology and study co-principal investigator, said in the release totky chote breast ko barhany k jo azmoda. "Any of these mechanisms put on the market potential new ways to treat the disease by interfering with those processes".